TickerFacts.

Scholar Rock Holding Corp (SRRK): Revenue

Annual figures by period end, from SEC filings.

$0
Year ended 2025-12-31
$0
Trailing 12 months to 2026-06-30
$33.19M2019-12-31: $20.49M2020-12-31: $15.40M2021-12-31: $18.82M2022-12-31: $33.19M2025-12-31: $0$0
2019-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$0n/a2026-03-03, From 2025-01-01
No annual figure between 2022-12-31 and 2025-12-31.
2022-12-31$33.19M+76.4%2024-03-19, From 2022-01-01
2021-12-31$18.82M+22.2%2023-03-07, From 2021-01-01
2020-12-31$15.40M-24.8%2022-03-07, From 2020-01-01
2019-12-31$20.49Mn/a2021-03-09, From 2019-01-01

Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Scholar Rock Holding Corp (SRRK)2025-12-31$0n/a
Vaxart, Inc. (VXRT)2025-12-31$237.26M+726.7%
Amgen Inc (AMGN)2025-12-31$36.75B+10.0%
Repligen Corp (RGEN)2025-12-31$738.26M+16.4%
Champions Oncology, Inc. (CSBR)2026-04-30$59.42M+4.4%
Bio-Techne Corp (TECH)2026-06-30$1.22B-0.4%
Biogen Inc. (BIIB)2025-12-31$9.89B+2.2%
Lineage Cell Therapeutics, Inc. (LCTX)2025-12-31$14.56M+53.2%
Gilead Sciences, Inc. (GILD)2025-12-31$29.44B+2.4%

Compare SRRK, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗